Victory Capital Management Inc. Has $372,000 Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Victory Capital Management Inc. trimmed its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 14.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,902 shares of the company’s stock after selling 2,441 shares during the period. Victory Capital Management Inc.’s holdings in Kiniksa Pharmaceuticals were worth $372,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in KNSA. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock valued at $58,833,000 after buying an additional 16,595 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at $71,000. Bayesian Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at $222,000. Linden Thomas Advisory Services LLC increased its stake in shares of Kiniksa Pharmaceuticals by 1.7% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company’s stock valued at $2,209,000 after buying an additional 1,921 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Kiniksa Pharmaceuticals by 261.3% in the 2nd quarter. SG Americas Securities LLC now owns 69,226 shares of the company’s stock valued at $1,292,000 after buying an additional 50,066 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Down 1.1 %

NASDAQ:KNSA opened at $22.08 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $15.82 and a 12-month high of $28.15. The firm has a market capitalization of $1.59 billion, a P/E ratio of -159.42 and a beta of 0.35. The stock’s fifty day simple moving average is $24.02 and its 200-day simple moving average is $22.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s revenue was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $36.60.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 53.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares in the company, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 95,192 shares of company stock worth $2,479,390. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.